2nd Quarter - Report

PODESTA GROUP, INC. for EISAI INC.

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Drug issues; FDA-DEA issues. Prescription Drug User Fee Act reauthorization. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. "Track and trace" legislation.

Foreign entity interest: Eisai Co., Ltd. to the degree that public policies, either laws or regulations, commercially benefit Eisai, Inc., so too Eisai Co., Ltd., as its parent, will benefit.

LobbyistCovered position, as disclosed
SHARON COHEN —
THOMAS B SPARKMAN —

Contacted: Treasury, Dept of; HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2516 (112th), H.R. 5651 (112th), S. 3187 (112th), S. 2292 (112th), H.R. 2112 (112th)

Health Issues HCR

Alzheimer's issues. Breast cancer efforts. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).

Foreign entity interest: Eisai Co., Ltd. to the degree that public policies, either laws or regulations, commercially benefit Eisai, Inc., so too Eisai Co., Ltd., as its parent, will benefit.

LobbyistCovered position, as disclosed
PAUL BRATHWAITE —
SHARON COHEN —
THOMAS B SPARKMAN —

Contacted: SENATE; Treasury, Dept of; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Medicare coverage and reimbursement issues. H. Con. Res 112, Establishing the budget for the US Government for FY 2013. Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).

Foreign entity interest: Eisai Co., Ltd. to the degree that public policies, either laws or regulations, commercially benefit Eisai, Inc., so too Eisai Co., Ltd., as its parent, will benefit.

LobbyistCovered position, as disclosed
SHARON COHEN —
THOMAS B SPARKMAN —

Contacted: Treasury, Dept of; HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.Con.Res. 112 (112th)

Financial Institutions/Investments/Securities FIN

Student Loan Auction Rate Securities (SLARS).

Foreign entity interest: Eisai Co., Ltd. to the degree that public policies, either laws or regulations, commercially benefit Eisai, Inc., so too Eisai Co., Ltd., as its parent, will benefit.

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: HOUSE OF REPRESENTATIVES; Treasury, Dept of; SENATE

Education EDU

Student Loan Auction Rate Securities (SLARS)

Foreign entity interest: Eisai Co., Ltd. to the degree that public policies, either laws or regulations, commercially benefit Eisai, Inc., so too Eisai Co., Ltd., as its parent, will benefit.

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: Treasury, Dept of; SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Branded prescription pharmaceutical fee under health care reform.

Foreign entity interest: Eisai Co., Ltd. to the degree that public policies, either laws or regulations, commercially benefit Eisai, Inc., so too Eisai Co., Ltd., as its parent, will benefit.

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Treasury, Dept of

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.